All the latest worldwide HIV and AIDS news, including treatment, prevention, and hepatitis and TB co-infections. News from our own team of writers plus articles we have selected from other sources.

aidsmap hiv & aids news

RSS

← First12345...859Next →

hiv & aids news selected from other sources

  • Vaccinations and immunisations
    Previous HAV vaccination does not reliably protect some patients with HIV
    Healio | 18 April 2019

    Study findings suggest that previous vaccination against hepatitis A virus infection does not reliably protect some people with HIV.

  • Elimination of hepatitis C
    England hits WHO 2020 hepatitis C target three years early
    The Pharmaceutical Journal | 18 April 2019

    Deaths from liver disease related to serious hepatitis C (HCV) fell by more than 16% between 2015 and 2017, according to data published by Public Health England (PHE). As a result, England has hit the World Health Organization’s (WHO’s) target to reduce HCV related mortality by 10% by 2020 three years early.

  • Pharmaceutical industry
    Gilead's first big TV push for triple combo Biktarvy showcases HIV diversity
    FiercePharma | 18 April 2019

    Gilead Sciences wanted to represent the wide range of people living with HIV in its first national TV campaign for Biktarvy. So they chose black, Latino, male, female, gay, bisexual and transgender actors for an ad that encourages people with HIV to “keep being you.”

  • New and experimental HIV treatments
    Novel Antibody May Suppress HIV for Up to Four Months
    NIAID | 18 April 2019

    Regular infusions of an antibody that blocks the HIV binding site on human immune cells may have suppressed levels of HIV for up to four months in people undergoing a short-term pause in their antiretroviral therapy (ART) regimens, according to a report published online today in The New England Journal of Medicine.

  • PrEP policies and guidelines
    Hivpoint Helsinki welcomes Pre-Exposure Prophylaxis – Finnish national guidelines are here, and generic medicines hit the market soon
    Hivpoint | 17 April 2019

    The National Institute for Health and Welfare recommends PrEP for people with a high risk for HIV transmission. As a part of a comprehensive prevention program, PrEP has reduced new HIV transmissions in all countries where it is available. When used correctly, PrEP provides up to 99% reduction in HIV risk. The Finnish national guidelines are released today, 17 April 2019.

  • People and personal stories
    Game Changers in HIV: Judith Currier
    The Body Pro | 17 April 2019

    Meet Judith Currier, M.D., a physician-researcher who paved the way for better treatment options for women living with HIV.

  • PrEP science
    Letter to FDA Regarding Application for Descovy as Pre-Exposure Prophylaxis for HIV
    Treatment Action Group | 17 April 2019

    TAG and PrEP4All sent this letter to Dr. Debra Birnkrant of the FDA, outlining and expressing our serious concerns about Gilead’s supplemental New Drug Application for Descovy (FTC/TAF) as HIV-1 preexposure prophylaxis (PrEP). There are several specific recommendations in the letter for this approval process, including recomending that the FDA convene a public meeting of the Antiviral Drug Advisory Committee.

  • PrEP programmes and uptake
    Pre-Exposure Prophylaxis for HIV officially launched in Hanoi
    Vietnam+ | 17 April 2019

    Pre-Exposure Prophylaxis (PrEP) service for HIV prevention was officially launched in Hanoi on April 16.

  • Hepatitis and HIV
    Hepatic Steatosis Highly Prevalent in Young Adults With Lifelong HIV
    Infectious Disease Advisor | 17 April 2019

    One-third of young adults living with HIV since birth or early childhood have hepatic steatosis.

  • Prevention of mother-to-child transmission
    Elvitegravir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1
    Medicines and Healthcare products Regulatory Agency | 17 April 2019

    Pharmacokinetic data indicate exposure of elvitegravir boosted with cobicistat (Genvoya, Stribild) is lower during the second and third trimesters of pregnancy than postpartum. Low elvitegravir exposure may be associated with an increased risk of treatment failure and an increased risk of HIV-1 transmission to the unborn child, and therefore elvitegravir/cobicistat should not be used during pregnancy.

← First12345...13Next →

Conference news

News from the Conference on Retroviruses and Opportunistic Infections (CROI 2019).

aidsmapLIVE

Watch our AIDS 2018 aidsmapLIVE panel discussion on YouTube.

HIV update

Sign up for HIV update, our fortnightly news bulletin for people living with HIV in the UK.

New EUROBulletin

Read the December edition of the Sexual Health & HIV Policy EUROBulletin.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.